226 related articles for article (PubMed ID: 35602486)
1. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.
Maliepaard M; Nibi P; Nibi G; Pasmooij AMG
Front Med (Lausanne); 2022; 9():893028. PubMed ID: 35602486
[TBL] [Abstract][Full Text] [Related]
2. Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.
Orellana García LP; Ehmann F; Hines PA; Ritzhaupt A; Brand A
Front Med (Lausanne); 2021; 8():753187. PubMed ID: 34790681
[No Abstract] [Full Text] [Related]
3. The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.
Enzmann H; Meyer R; Broich K
Biomark Med; 2016 Dec; 10(12):1261-1268. PubMed ID: 27661101
[TBL] [Abstract][Full Text] [Related]
4. Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union.
Verbaanderd C; Trullás Jimeno A; Engelbergs J; Zander H; Reischl I; Moreno Oliver A; Vamvakas S; Vleminckx C; Bouygues C; Girard T; Day F; Frias Z
Clin Pharmacol Ther; 2023 Aug; 114(2):316-324. PubMed ID: 37132507
[TBL] [Abstract][Full Text] [Related]
5. A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines.
Garsen M; Steenhof M; Zwiers A
Ther Innov Regul Sci; 2021 Jul; 55(4):633-642. PubMed ID: 33543409
[TBL] [Abstract][Full Text] [Related]
6. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
7. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European
Vanstapel FJLA; Orth M; Streichert T; Capoluongo ED; Oosterhuis WP; Çubukçu HC; Bernabeu-Andreu FA; Thelen M; Jacobs LHJ; Linko S; Bhattoa HP; Bossuyt PMM; Meško Brguljan P; Boursier G; Cobbaert CM; Neumaier M
Clin Chem Lab Med; 2023 Mar; 61(4):608-626. PubMed ID: 36716120
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation.
Wollenhaupt C; Sudhop T; Knoess W
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370933
[TBL] [Abstract][Full Text] [Related]
9. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
10. Companion Diagnostics: State of the Art and New Regulations.
Valla V; Alzabin S; Koukoura A; Lewis A; Nielsen AA; Vassiliadis E
Biomark Insights; 2021; 16():11772719211047763. PubMed ID: 34658618
[TBL] [Abstract][Full Text] [Related]
11. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
12. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
13. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.
Tafuri G; Pagnini M; Moseley J; Massari M; Petavy F; Behring A; Catalan A; Gajraj E; Hedberg N; Obach M; Osipenko L; Russo P; Van De Casteele M; Zebedin EM; Rasi G; Vamvakas S
Br J Clin Pharmacol; 2016 Oct; 82(4):965-73. PubMed ID: 27245362
[TBL] [Abstract][Full Text] [Related]
14. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
15. Ethics and the marketing authorization of pharmaceuticals: what happens to ethical issues discovered post-trial and pre-marketing authorization?
Bernabe RDLC; van Thiel GJMW; Breekveldt NS; Gispen CC; van Delden JJM
BMC Med Ethics; 2020 Oct; 21(1):103. PubMed ID: 33109181
[TBL] [Abstract][Full Text] [Related]
16. A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model.
Bergman E; Pasmooij AMG; Mol PGM; Westman G
PLoS One; 2023; 18(12):e0294560. PubMed ID: 38100432
[TBL] [Abstract][Full Text] [Related]
17. Current european regulatory perspectives on insulin analogues.
Enzmann HG; Weise M
Diabetol Metab Syndr; 2011 Jul; 3():14. PubMed ID: 21736748
[TBL] [Abstract][Full Text] [Related]
18. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
20. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.
Elsäßer A; Regnstrom J; Vetter T; Koenig F; Hemmings RJ; Greco M; Papaluca-Amati M; Posch M
Trials; 2014 Oct; 15():383. PubMed ID: 25278265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
